A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Nov 1, 2013

Astellas Announces Acquisition of Own Shares

Read more about Astellas Announces Acquisition of Own Shares
Nov 1, 2013

Astellas signs agreement with Accenture for Business Process Outsourcing - Focusing on operational excellence to respond resiliently to changing business environment for sustainable growth -

Tokyo, November 1, 2013 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) has signed an agreement with Accenture Japan Ltd. (headquarters: Tokyo, President:...

Read more about Astellas signs agreement with Accenture for Business Process Outsourcing - Focusing on operational excellence to respond resiliently to changing business environment for sustainable growth -
Oct 22, 2013

Medivation and Astellas Announce The Phase 3 PREVAIL Trial of Enzalutamide Meets Both Co-Primary Endpoints of Overall Survival and Radiographic Progression-Free Survival in Chemotherapy-Naïve Patients With Advanced Prostate Cancer

San Francisco, CA and Tokyo – October 22, 2013 – Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced that the Independent Data Monitoring Committee (IDMC) has...

Read more about Medivation and Astellas Announce The Phase 3 PREVAIL Trial of Enzalutamide Meets Both Co-Primary Endpoints of Overall Survival and Radiographic Progression-Free Survival in Chemotherapy-Naïve Patients With Advanced Prostate Cancer
Oct 21, 2013

Astellas and UMN announce Completion of Administration of Phase III Clinical Trials of Seasonal Flu Vaccine ASP7374

Astellas Pharma Inc. (TSE: 4503; Headquaters: Tokyo; President & CEO: Yoshihiko Hatanaka) and UMN Pharma Inc. (TSE: 4585; Headquaters: Akita; CEO: Tatsuyoshi Hirano) today announced that the...

Read more about Astellas and UMN announce Completion of Administration of Phase III Clinical Trials of Seasonal Flu Vaccine ASP7374
Oct 2, 2013

Astellas Enters License Agreement with Janssen to Develop and Commercialize ASP015K, an Astellas’ Oral JAK Inhibitor for Immunologic Diseases

Read more about Astellas Enters License Agreement with Janssen to Develop and Commercialize ASP015K, an Astellas’ Oral JAK Inhibitor for Immunologic Diseases

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts